Is methisoprinol (inosine pranobex) safe for use during breastfeeding?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 21, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Methisoprinol Safety During Breastfeeding

There is insufficient safety data on methisoprinol (inosine pranobex) use during breastfeeding, and it should be avoided until further evidence becomes available.

Evidence Assessment

The provided evidence does not contain any specific information about methisoprinol (inosine pranobex) and breastfeeding. The FDA drug label references 1 are actually for metyrapone (Metopirone), which is a completely different medication - an adrenal steroid synthesis inhibitor, not methisoprinol.

Key Distinction

  • Metyrapone (referenced in the drug labels): Used for diagnosing adrenal insufficiency
  • Methisoprinol/Inosine pranobex: An immunomodulatory and antiviral agent

These are entirely different drugs with different mechanisms of action.

What We Know About Methisoprinol

Based on the research evidence provided:

  • Methisoprinol is a purine derivative with immunopharmacological effects 2
  • It has been studied for various viral infections and immune conditions 2, 3
  • No data exists in the provided evidence regarding its excretion in breast milk or effects on breastfed infants

Clinical Recommendation

Given the complete absence of safety data:

  • Avoid methisoprinol during breastfeeding until adequate safety information becomes available
  • If treatment is absolutely necessary, consider alternative medications with established safety profiles during lactation
  • If no alternatives exist and the maternal condition requires treatment, a risk-benefit discussion should include:
    • The severity of the maternal condition
    • Availability of safer alternatives
    • Potential for temporary cessation of breastfeeding during treatment
    • The infant's age and health status

General Principles for Unknown Medications

When prescribing any medication with limited lactation data 4, 5:

  • Consider the drug's molecular weight, protein binding, and half-life
  • Assess the infant's age (younger infants are at higher risk)
  • Evaluate the duration of maternal treatment needed
  • Monitor the infant for any unusual symptoms if exposure occurs

The absence of evidence is not evidence of safety - this principle is particularly important for medications like methisoprinol where no breastfeeding data exists.

References

Research

Drugs in lactation.

The journal of obstetrics and gynaecology research, 2019

Research

Drugs and breastfeeding: instructions for use.

The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians, 2012

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.